linjc16/ctgov huggingface dataset:
A New Pelvic Osteotomy Method for Open Reduction

Study Overview
=================
Brief Summary
-----------------
Developmental dysplasia of the hip (DDH) was one of the most common hip disorders disease in children. Pemberton osteotomy (PO) was one of the most widely used by the pediatric orthopedic surgeons. In our clinical work, the investigators found some defect the operation procedure. When the surgeons were not familiar to the PO, it may injured the triradiate cartilage or easily be absorbable of the distal iliac. Here, the investigators found a new pelvic osteotomy just from the inner L shaped iliac osteotomy (ILSO) to treat DDH. This approach was in a visible part of the sciatic notch and not presumed to be in the ischium, completely out of sight. Comparing to the PO method, the investigators' operation method was easy to master and had less complications.

Official Title
-----------------
A New Pelvic Osteotomy Method for Open Reduction in the Treatment of Developmental Dysplasia of the Hip in Children

Conditions
-----------------
Developmental Dysplasia of the Hip

Intervention / Treatment
-----------------
* Procedure: a new osteotomy from the inner L shaped iliac osteotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over two years old open reduction and acetabular osteotomy diagnosed as developmental dysplasia of the hip Exclusion Criteria: a previous history of DDH surgery teratologic dislocations cerebral palsy other spastic or neuromuscular disease

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pemberton osteotomy （PO）<br>PO group received Pemberton osteotomy | |
| inner L shaped iliac osteotomy (ILSO)<br>ILSO group received inner L shaped iliac osteotomy | Procedure: a new osteotomy from the inner L shaped iliac osteotomy<br>* There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| preoperative acetabular index | preoperative acetabular index by measure the postoperative X-ray | 6th month after surgery | 
| Wiberg's mean center-edge angle | center-edge angle by measure the postoperative X-ray | 6th month after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood loss | blood loss during surgery | 1st day after surgery | 
| avascular necrosis (AVN) | avascular necrosis (AVN) of the femoral head according to the Kalamchi and McEwen classification | through study completion, an average of 1 year |
Safety and Efficacy Evaluation of Decitabine With R-GDP

Study Overview
=================
Brief Summary
-----------------
Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients

Detailed Description
-----------------
RR NHL patients will be treated with decitabin plus R-GDP , safety and efficacy will be assessed.

Official Title
-----------------
Safety and Efficacy Evaluation of Decitabine With R-GDP on Refractory or Relapsed NHL Patients

Conditions
-----------------
NHL

Intervention / Treatment
-----------------
* Drug: Decitabine and R-GDP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Relapsed or refractory Non-Hodgkin's lymphoma(NHL) patiens. Eastern Cooperative Oncology Group(ECOG) score 0-2 Expected survival >3 months Measurable disease. Exclusion Criteria: Patients who needs treatment with immunosuppressive agents Hematosepsis or Uncontrolled active infection History of epilepsy or other CNS disease. Active hepatitis B , hepatitis C or HIV infection or any other uncontrolled active infection. Pregnancy or breast-feeding women. Any uncontrolled medical disorders that the researchers considered are not suitable to participate the clinical trial. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluatio

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Decitabine and R-GDP<br>ALL patients will be treated with Decitabine and R-GDP | Drug: Decitabine and R-GDP<br>* Decitabine and R-GDP<br>* Other names: DR;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall survival | 2 years |
Sleep in Women With Bilateral Salpingo-Oophorectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is the compare objective and subjective sleep characteristics in women who have undergone removal of both ovaries (bilateral salpingo-oophorectomy) before natural menopause compared to women who did not undergo this procedure.

Official Title
-----------------
Assessment of Sleep Disruption in Women With Bilateral Salpingo-Oophorectomy - A SCORE Ancillary Study

Conditions
-----------------
Bilateral Salpingo-oophorectomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who participate in the parent SCORE studies (NCT03821857) Exclusion Criteria: Night shift workers will be excluded

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with bilateral salpingo-oophorectomy (BSO)<br> | |
| Women without bilateral salpingo-oophorectomy (BSO)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of sleep disorders | prevalence of sleep disordered breathing, insomnia, and restless legs syndrome | 2 years | 
| prevalence of short sleep duration | objective sleep duration from actigraphy/polysomnography and subjective sleep duration from self-report | 2 years | 
| prevalence of poor sleep quality | objective sleep quality from actigraphy/polysomnography and subjective sleep quality from self-report | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
salpingo-oophorectomy, sleep, cognitive decline
The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic Sclerosis

Study Overview
=================
Brief Summary
-----------------
The effect of deep oscillation and biofeedback on Raynaud's phenomenon secondary to systemic sclerosis (SSc) remains to be determined. A prospective randomized controlled pilot study was performed in SSc patients receiving either deep oscillation, biofeedback thrice a week for four weeks or were randomized to the control group.

Official Title
-----------------
A Prospective Randomized Controlled Study Analyzing the Effect of Biofeedback and Deep Oscillation on Raynaud´s Phenomenon Secondary to Systemic Sclerosis

Conditions
-----------------
Raynaud's Phenomenon, Systemic Sclerosis

Intervention / Treatment
-----------------
* Other: Biofeedback
* Other: Deep oscillation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ACR criteria for SSc Exclusion Criteria: acute inflammatory disease, Valentini Score>3

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: physical therapy<br> | Other: Biofeedback<br>* Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.<br>Other: Deep oscillation<br>* Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.<br>|
| No Intervention: control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RP score , measured by a visual analogue scale (VAS) |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ulceration of the skin and general disease symptoms using analogous VAS-scores |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Raynaud's phenomenon, biofeedback, deep oscillation, systemic sclerosis, physiotherapy
Nexium Capsules LDA Specific Clinical Experience Investigation

Study Overview
=================
Brief Summary
-----------------
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Detailed Description
-----------------
Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Official Title
-----------------
Nexium Capsules Specific Clinical Experience Investigation for Long-term Use Concerning Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer With LDA

Conditions
-----------------
Gastric Ulcer, Duodenal Ulcer

Participation Criteria
=================
Eligibility Criteria
-----------------
Exclusion Criteria: Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy). Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nexium<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events incidence | Number of Adverse Drug Reactions | Up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non-recurrence rate of peptic ulcer |  | Up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low dose Aspirin(LDA), Gastric ulcer or duodenal ulcer, Nexium
Registry Evaluation of a Double Balloon Accessory Device

Study Overview
=================
Brief Summary
-----------------
This study is collecting standard of care information pertaining to the use of the accessory device and patient outcomes when this double balloon accessory device is used during endoscopic procedures in the colon.

Official Title
-----------------
Multi-center Prospective Registry Study Utilizing a Double Balloon Accessory Device to Facilitate Endoscopic Polypectomy in Large Intestine.

Conditions
-----------------
Adenomatous Polyp of Colon

Intervention / Treatment
-----------------
* Device: Double balloon accessory device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for endoscopic removal of suspected adenomatous benign polyps(s) Patients capable of giving informed consent in English No medical contraindication to endoscopic mucosal resection or endoscopic submucosal disection Exclusion Criteria: No patients less than 18 years of age. Any contraindication to colonoscopy with due to subject's colon anatomy (i.e. stricture) History of open or laparoscopic colorectal surgery History of Inflammatory Bowel Disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Double balloon accessory device|Double balloon accessory device is used during the endoscopic polypectomy procedure|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability to perform the procedure safely and effectively with the study device. | Investigator answers yes or no | Intraoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to reach target lesion | Time measurement in hours and minutes | Intraoperatively | 
| Time to remove lesion after intervention begins | Time measurement in hours and minutes | Intraoperatively | 
| Total time using study device during case | Time measurement in hours and minutes | Intraoperatively | 
| Total case time | Time measurement in hours and minutes | Intraoperatively | 
| Total defect closure time | Time measurement in hours and minutes | Intraoperatively | 
| User feedback on device performance | Investigator rates the ease of use (easy, somewhat easy, somewhat difficult and difficult) of the device. | Intraoperatively | 
| Number of Study Subjects with Treatment Related Adverse Events | No moderate to severe mucosal injury, perforations or bleeding related to the use of the device. | Up to 30 days |
Vaginal vs. Laparoscopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Hysterectomy for benign indication is one of the most common surgical procedures in women. Numerous reviews and guidelines recommend the vaginal approach for benign hysterectomy, but the proportion of laparoscopic (and robotic) hysterectomies is increasing. This study will compare a range of clinical and subjective outcomes of vaginal vs. total laparoscopic hysterectomy. Outcomes include operating time, postoperative recovery, return to work as well as cosmesis, quality of life and sexual health.

Official Title
-----------------
Vaginal Hysterectomy Versus Total Laparoscopic Hysterectomy for Benign Indications: A Randomized Controlled Trial

Conditions
-----------------
Uterine Fibroids, Uterine Leiomyoma, Abnormal Uterine Bleeding, Unspecified

Intervention / Treatment
-----------------
* Procedure: Hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: benign indication for vaginal hysterectomy (e.g., abnormal uterine bleeding, fibroids, atypical endometrial hyperplasia) clinical exam indicates vaginal hysterectomy is feasible no major concomitant surgery able to complete questionnaires in German Exclusion Criteria: uterine malignancy major concomitant surgery (e.g., for incontinence or prolapse) clinical exam indicating vaginal hysterectomy not feasible contraindication for surgery or laparoscopy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Vaginal hysterectomy<br>Vaginal hysterectomy | Procedure: Hysterectomy<br> <br> |
| Active Comparator: Total laparoscopic hysterectomy<br>Laparoscopic hysterectomy | Procedure: Hysterectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operating time (min.) | Operating time (min.) | Surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications | Intraoperative and postoperative complications | 6 weeks | 
| Anesthesia time (min.) |  | surgery | 
| Quality of life |  | 12 months | 
| Sexual health |  | 12 months | 
| Return to work |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hysterectomy
Systematic Review and Meta-analysis of Cereal or Grain Consumption and Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
This project involved a systematic literature review of published trials of cereal or grain in relation to the risk of gastric cancer. Data was extracted from the publications on PubMed, EMBASE, Cochrane Library.A traditional meta-analysis, subgroup analysis, and heterogeneity was conducted on the extracted data.

Detailed Description
-----------------
Investigators searched PubMed, EMBASE, Cochrane Library for studies focusing on cereal or grain in relation to the risk of gastric cancer up to October 2017. Summary odd ratios (OR) and 95% confidence intervals (CI) were calculated by using either random effect models or fixed effect models according to the heterogeneity of included studies. Subgroup analysis, heterogeneity, and publication bias were also performed.

Official Title
-----------------
Cereal or Grain Consumption and Gastric Cancer Risk: a Systematic Review and Meta-analysis of Observational Studies

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Dietary Supplement: cereal or grain consumption


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a case-control studies or a cohort study investigate the association between cereal or grain intake and GC occurrence report an odds ratio (OR) or relative risk (RR) with corresponding 95% confidence intervals (CI) provide sufficient data to estimate OR or RR Exclusion Criteria: Non-human studies GC mortality-based cohort studies
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gastric cancer<br> | Dietary Supplement: cereal or grain consumption<br>* intake of cereal, whole grain, refined grain, and other grain of every day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the relationship between overall cereal consumption and gastric cancer occurance | perform a pooled analysis of included studies with OR through STATA 12.0 | up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the relationship between whole grain and gastric cancer occurance | perform a subgroup analysis to summarize the related OR through STATA 12.0 | up to 2 years | 
| the relationship between refined grain and gastric cancer occurance | perform a subgroup analysis to summarize the related OR through STATA 12.0 | up to 2 years | 
| the relationship between other grain and gastric cancer occurance | perform a subgroup analysis to summarize the related OR through STATA 12.0 | up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cereal, whole grain, refined grain, gastric cancer, meta analysis
Does Local Morphine Add to Local Anesthetics in Serratus Anterior Plane Block Has a System Analgesic Effect?

Study Overview
=================
Brief Summary
-----------------
the investigators aim is to investigate and explore the effect 10 mg morphine added to local anesthetics in serratus anterior plane block for post mastectomy pain management after modified radical mastectomy in patients with breast cancer with assessment of its serum level if it will be absorbed systemically or not?

Official Title
-----------------
Does Local Morphine Add to Local Anesthetics in Serratus Anterior Plane Block for Post Mastectomy Pain Has a System Analgesic Effect? A Clinical and Pharmacokinetics Study

Conditions
-----------------
Postoperative Complications

Intervention / Treatment
-----------------
* Drug: Morphine Sulfate
* Drug: Bupivacaine Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (ASA) class I-II body weight of 50 - 90 kg Exclusion Criteria: a history of bleeding diathesis, relevant drug allergy, opioid dependence, sepsis, prior surgery in the supraclavicular, infraclavicular or axillary regions, alcohol or drug abuse , patients with advanced cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: morphine sulphate<br>10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle | Drug: Morphine Sulfate<br> <br> * Other names: morphine;|
| Placebo Comparator: bupivacaine hydrochloride<br>0.25%locally bupivacaine hydrochloride once | Drug: Bupivacaine Hydrochloride<br> <br> * Other names: marcaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum morphine level after local injection | concentration of serum morphine in ng/ml after local injection | 24 hours |